Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
Date:9/30/2009

s of AT2220 on glycogen reduction in an appropriate transgenic mouse model of Pompe disease. Preliminary results of this study demonstrate consistent glycogen reduction across a range of different tissues, including heart, diaphragm and multiple skeletal muscles. Glycogen is the substrate that accumulates in the cells of patients with Pompe disease, which is believed to result in the clinical symptoms of the disease. The Company expects to present the results of this and other preclinical studies at appropriate scientific conferences in 2010.

Additionally, Amicus continues to be encouraged by the results of preclinical studies designed to evaluate the use of AT2220 in combination with enzyme replacement therapy (ERT). The Company expects to report additional data from these studies at scientific conferences in 2010.

About Pompe Disease

Pompe disease affects an estimated 5,000 to 10,000 individuals world-wide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive muscle weakness and respiratory insufficiency. A high majority of people with Pompe disease have the late onset form. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as ph
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 The Market Element LLC, a ... alliance with Designing Gig LLC to provide website design, ... , “Forging this alliance with Designing Gig represents a ... extend a comprehensive, end-to-end, digital solution for our clients, ... said Chuck Miller, president of The Market Element. “For ...
(Date:3/26/2015)... LANSING, Mich., March 26, 2015 Neogen Corporation ... income for the third quarter of fiscal 2015, which ... to the prior year,s $6,575,000. Earnings per share in ... year ago. Current year-to-date net income increased 17% over ... to $20,621,000, or $0.56 per share, for the same ...
(Date:3/26/2015)... "In America," the popular news television program that ... hosted by legendary film actor James Earl Jones, has announced ... upcoming segment. , Botany is commonly described as the ... quite a bit more complicated than that. Scientists and other ... organisms, from the smallest bacteria known to man to the ...
(Date:3/25/2015)... pharmaceutical market is one of the most ... its absolute size, plus a growing economy and increasing ... Business Monitor International. The Russian market is set to ... market, with growth estimates around 10-15% annually reaching an ... About Green Cross Green Cross provides ...
Breaking Biology Technology:The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... , , , , , ... company,providing customized enzymes to the pharmaceutical, chemical, and other,industries, announced today ... from existing shareholders. , The Company ... product portfolio and to accelerate the development of international,markets. At the ...
... , This release is available in German ... display case. A white light appears out of nowhere. And ... glance. Only upon close examination does the source of the ... a pinhead, passes through thousands of infinitesimal lens structures measuring ...
... EMERYVILLE, Calif. , Feb. 2 Onyx Pharmaceuticals, ... at the 12th Annual BIO CEO & Investor Conference on ... ( 5:30 a.m. Pacific Time ).  Interested parties may access ... , http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , It is recommended that listeners log ...
Cached Biology Technology:EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets 2EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets 3Nano for the senses 2Nano for the senses 3Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 2
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
(Date:3/11/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has ... by Product, Application & By Geography - Global Forecast ... , This report predicts that the access ... 2020, with an estimated CAGR of 10.6%. ... such as contact cards & readers, contactless cards & ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... report in the journal Development ( dev.biologists.org ... of a type of cell that can make myelin, ... basic and clinical research. The cells the researchers ... myelin in the central nervous system. Myelin forms an ...
... field stations have long been home to a rich ... places for serendipitous discoveries in the biological and environmental ... issue of the journal BioScience , researchers affiliated ... Research (LTER) Network and other groups state that few ...
... as contributing to autoimmune disease, but a review appearing ... of vitamin D in patients with autoimmune disease may ... and that supplementing with vitamin D may actually exacerbate ... at the California-based non-profit Autoimmunity Research Foundation, the paper ...
Cached Biology News:Human ES cells progress slowly in myelin's direction 2Field stations foster serendipitous discoveries in environmental, biological sciences 2Field stations foster serendipitous discoveries in environmental, biological sciences 3Vitamin D may exacerbate autoimmune disease 2
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
... HT, 1 kit. Facilitates the simple, phenol-free ... and hard tissue requiring proteinase K digestion.Each ... DNA from 50 preparations of up to ... Synthesis & Purification, Purification and Amplification of ...
... For rapid and efficient purification of DNA ... 15 minutes by gravity flow.Prepacked with Sephadex ... 0.15% Kathon CG/ICP Biocide.Available in three sizes ... (NAP-5), 1 ml (NAP-10) or 2.5 ml ...
Human ROR1 Affinity Purified Polyclonal Ab...
Biology Products: